Does Amarin Have the Right Management Team?

Before you go, we thought you'd like these...
Before you go close icon

Biopharmaceutical company Amarin (NAS: AMRN) won approval from the Food and Drug Administration for its hypertriglyceridemia drug Vascepa in July. Speculation surrounding an Amarin buyout has ebbed and flowed in the past few months. Most recently, rumors emerged that AstraZeneca (NYS: AZN)  -- a struggling pharma giant that could turn the page with its new chief executive -- might be interested in making a bid. If opportunity knocks and Amarin does in fact receive an offer, can investors trust the company's management to negotiate a good deal?

To help you weigh both the opportunities and risks associated with this stock, we're launching a brand new premium report on Amarin. The following - which focuses on Amarin's leadership-is only a small sample of what you'll find in the complete report.

Leadership
Amarin has had five different chief executives over the past decade, but it currently has the ideal management team to carry the company forward. CEO Joseph Zakrzewski is an industry veteran who served as the COO of Reliant Pharmaceuticals -- which coincidentally licensed the U.S. rights to Lovaza from Norwegian drugmaker ProNova BioPharma.


That's right: Amarin's CEO was an integral part of the company that commercialized Vascepa's chief competitor in the hypertriglyceridemia space. Zakrzewski was also at Reliant when the company was sold to GlaxoSmithKline  (NYS: GSK)  in 2007 for a hefty $1.65 billion. I bet he knows his way around a negotiating table, and these skills might come in handy if Amarin starts to aggressively look for a buyer.

Amarin also has a management team that can capably launch Vascepa if it decides to fly solo. The company's chief commercial officer, Paul Huff, and president of R&D, Steven Ketchum, also held senior management positions at Reliant during the commercialization of Lovaza.

We hope you enjoyed this sample of our new premium research report on Amarin. To gain access to the complete report and a full year of updates, click here to keep reading today.

The article Does Amarin Have the Right Management Team? originally appeared on Fool.com.

Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners